×
About 2,020 results

ALLMedicine™ Sensory Neuropathy Center

Research & Reviews  693 results

Are Miller Fisher syndrome and CANDA due to a paranodopathy?
https://doi.org/10.1016/j.jns.2022.120279
Journal of the Neurological Sciences; Vallat JM, Deschamps N et. al.

May 17th, 2022 - To study the pathological characteristics of acute and chronic ataxic peripheral neuropathy at the level of the node of Ranvier. We performed the pathological study (nerve biopsy of a sural nerve) of two patients, one with an acute form of ataxic ...

Ultrasonography as a diagnostic tool for Neural Pain in Leprosy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094535
PLoS Neglected Tropical Diseases; Spitz CN, Mogami R et. al.

Apr 30th, 2022 - Leprosy is still a prevalent disease in Brazil, representing 93% of all occurrences in the Americas. Leprosy neuropathy is one of the most worrying manifestations of the disease. Acute neuropathy usually occurs during reaction episodes and is call...

Effects of orthopedic footwear on postural stability and walking in individuals with He...
https://doi.org/10.1016/j.clinbiomech.2022.105638
Clinical Biomechanics (Bristol, Avon); de Jong LAF, Kerkum YL et. al.

Apr 12th, 2022 - Orthopedic footwear is often prescribed to improve postural stability during standing and walking in individuals with Hereditary Motor Sensory Neuropathy. However, supporting evidence in literature is scarce. The aim of this study was to investiga...

Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadj...
https://doi.org/10.2217/nnm-2022-0025
Nanomedicine (London, England); Zhang W, Xu Y et. al.

Apr 9th, 2022 - Aim: The present study aimed to retrospectively compare the efficacy and safety between liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P) in neoadjuvant systemic treatment (NST) of breast cancer. Materials & methods: 2...

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02037529

Apr 8th, 2022 - PRIMARY OBJECTIVES: I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witherib...

see more →

Guidelines  1 results

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on man...
https://doi.org/10.1111/j.1529-8027.2010.00278.x
Journal of the Peripheral Nervous System : JPNS;

Nov 3rd, 2010 - The aim of this guideline is to update the 2006 EFNS/PNS guideline on management of patients with a demyelinating neuropathy and a paraprotein (paraproteinemic demyelinating neuropathy [PDN]) by review of evidence and expert consensus. In the abse...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  22 results

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02037529

Apr 8th, 2022 - PRIMARY OBJECTIVES: I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witherib...

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
https://clinicaltrials.gov/ct2/show/NCT03693677

Mar 24th, 2022 - Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associat...

PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA
https://clinicaltrials.gov/ct2/show/NCT03006432

Mar 24th, 2022 - Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a cure. The vast majority of patients, however, present with adv...

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
https://clinicaltrials.gov/ct2/show/NCT04787354

Feb 21st, 2022 - XELOX (oxaliplatin + capecitabine) combination chemotherapy is considered a standard adjuvant treatment for curatively resected gastric cancer patients after it proved its effecacy in the CLASSIC trial. Adjuvant XELOX chemotherapy is a long-term t...

Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
https://clinicaltrials.gov/ct2/show/NCT01499940

Nov 10th, 2021 - Oxaliplatin is used most frequently in patients with metastatic and early-stage colorectal cancers. It has been found that in the adjuvant setting, Oxaliplatin improves both disease free and overall survival. Despite these results, the use of Oxal...

see more →

News  87 results

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/neoadjuvant-enfortumab-vedotin-demonstrates-encouraging-activity-in-cisplatin-ineligible-muscle-invasive-bladder-cancer

Mar 18th, 2022 - Enfortumab vedotin (Padcev) produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer (MIBC) who were not eligible for cisplatin, according to preliminary findings from cohort H of the...

FDA Grants Priority Review to 2 sBLAs for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
https://www.onclive.com/view/fda-grants-priority-review-to-2-sblas-for-enfortumab-vedotin-in-locally-advanced-or-metastatic-urothelial-cancer

Mar 1st, 2022 - The FDA has granted priority review to 2 supplemental biologics license applications (sBLAs) for enfortumab vedotin-ejfv (Padcev) for the treatment of select patients with locally advanced or metastatic urothelial cancer.1 The first application...

Germline Signatures of Toxicity: A Fertile Field
https://www.medscape.com/viewarticle/962787

Dec 23rd, 2021 - This transcript has been edited for clarity. I'm David Kerr, professor of cancer medicine from the University of Oxford. Today, I'd like to talk about a study from Annals of Oncology, written by a group of distinguished Japanese investigators, sev...

Brentuximab Vedotin Plus Chemo Shows Strong Activity in Early-Stage Hodgkin Lymphoma
https://www.onclive.com/view/brentuximab-vedotin-plus-chemo-shows-strong-activity-in-early-stage-hodgkin-lymphoma

Oct 6th, 2021 - The combination of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (AVD) with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorab...

see more →

Patient Education  3 results see all →